Federal Express Corporation, one of the world’s largest express transportation companies, announced today that its hubs at Guangzhou Baiyun International Airport, China (CAN) and Kansai International Airport, Japan (KIX) have been awarded with the prestigious CEIV Pharma Corporate Certification. This marks a significant milestone in the company’s ongoing commitment to quality, compliance, and leadership in pharmaceutical logistics.
The Center of Excellence for Independent Validators (CEIV) Pharma Certification, from the International Air Transport Association (IATA), ensures the highest standards in the handling and transportation of time and temperature sensitive healthcare products such as pharmaceutical and vaccines across air networks. This corporate-level certification is a testament of the strength of FedEx’s quality management system and its expertise in delivering fully compliant, end-to-end logistic services that meet the rigorous demands of the increasingly complex and highly regulated pharmaceutical industry.
“Healthcare innovation demands smarter, faster, and more resilient supply chains,” said Kawal Preet, President, Asia Pacific, FedEx. “As Asia Pacific rapidly emerges as a global hub for clinical trials and biopharma manufacturing, the need for secure, compliant, and technology-enabled logistics is more important than ever. Our proven expertise in building intelligent cold chain solutions is designed to protect product integrity, ensure regulatory compliance, and deliver peace of mind to our customers. By combining our global network with AI-driven logistics and real-time monitoring, FedEx is helping healthcare and life sciences companies unlock speed, scale, and reliability, supporting the next wave of healthcare innovation across the region.”
The Asia Pacific Pharmaceutical Logistics market is projected to grow from USD 163 billion in 2025 to USD 225 billion by 2030, reflecting a CAGR of 6.68%. Additionally, the region accounts for approximately 50% of global clinical trials2, highlighting its vital role in global pharmaceutical research and development. Customers in the healthcare and pharmaceutical sector need closed loop temperature-controlled services to preserve temperature integrity to ensure product efficacy. With decades of experience, FedEx provides expertise in customized solutions for clinical trial solutions, biologics and vaccines enabled by its robust International Express network, customized Time Critical Special Services (SpS), and a global network of Life Science Centers in Incheon (Korea), Singapore, Tokyo (Japan), Mumbai (India), Memphis (United States), and Veldhoven (the Netherlands). The company’s extensive healthcare infrastructure also includes 130+ cold-chain facilities worldwide, ensuring continuous temperature integrity for shipments moving through our domestic and international networks.
The certifications at Guangzhou Baiyun International Airport, China (CAN) and Kansai International Airport, Japan (KIX) are part of a broader FedEx initiative to expand CEIV-compliant infrastructure globally. As of May 2025, a total of nineteen FedEx facilities worldwide, including key locations in Europe and the Americas, will operate under the CEIV Pharma quality framework further strengthening the company’s position as a trusted logistics partner for the global healthcare industry.
